+

WO2013081366A1 - Composition destinée au nettoyage de la cavité nasale contenant de l'eau minérale - Google Patents

Composition destinée au nettoyage de la cavité nasale contenant de l'eau minérale Download PDF

Info

Publication number
WO2013081366A1
WO2013081366A1 PCT/KR2012/010154 KR2012010154W WO2013081366A1 WO 2013081366 A1 WO2013081366 A1 WO 2013081366A1 KR 2012010154 W KR2012010154 W KR 2012010154W WO 2013081366 A1 WO2013081366 A1 WO 2013081366A1
Authority
WO
WIPO (PCT)
Prior art keywords
mineral water
composition
present
nasal
rhinitis
Prior art date
Application number
PCT/KR2012/010154
Other languages
English (en)
Korean (ko)
Inventor
윤건호
김동현
김정득
Original Assignee
가톨릭대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가톨릭대학교 산학협력단 filed Critical 가톨릭대학교 산학협력단
Publication of WO2013081366A1 publication Critical patent/WO2013081366A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Definitions

  • the present invention relates to a composition for washing the nasal cavity containing mineral water and a pharmaceutical composition capable of preventing or treating rhinitis and sinusitis.
  • Rhinitis refers to inflammation occurring in the nasal mucosa inside the nose, which is the respiratory organ of the human body, and includes acute and chronic rhinitis, viral rhinitis due to cold, and allergic rhinitis. Symptoms include a runny nose (a benign nasal mucus) and a stuffy nose (nasal obstruction). In general, infection with rhinitis not only causes difficulty breathing, but also causes symptoms such as headache or attention deterioration, which causes greater discomfort, and is rarely cured despite long-term treatment. The disease recurs afterwards, making treatment difficult.
  • allergic rhinitis or sinusitis causes chronic oxygen deficiency due to nasal congestion, which significantly reduces brain function. Therefore, children or adolescents with rhinitis or sinusitis often have chronic fatigue and learning disabilities, and even those with heavy workloads cause a lot of disruptions due to lower work efficiency.
  • paranasal sinuses are located around the nose and filled with bone-filled air.
  • the main paranasal sinuses are the frontal sinus located above both eyebrows, the maxillary sinus located on the face below both eyes, the ethmoid sinus located between both eyes, and the sphenoid sinus deep behind the nose. have.
  • the paranasal sinuses are covered with the same type of mucosa as the nasal mucosa.
  • the nasal and paranasal sinuses produce mucous secretions daily, from which the nasal secretions exit through the natural openings leading to the small sized pencil-holes in the nose.
  • the obstruction of the sinus outlet may be caused by anatomical causes, irritants, or allergies in the nose, and sinus disease may occur frequently in the same family, and stress may be a cause of chronic sinus disease as well as nasal obstruction. May cause excessive breathing in the lungs and make asthma worse.
  • antiallergic or antihistamines are prescribed for the treatment of nasal diseases including rhinitis.
  • antihistamines have side effects of frequent relapses and drowsiness, and topical steroids sprayed on the nose also eliminate symptoms at the moment of use, but they can cause sinusitis if used for a long time.
  • topical steroids sprayed on the nose also eliminate symptoms at the moment of use, but they can cause sinusitis if used for a long time.
  • the nasal congestion is severe, there is a problem that the laser surgery is expensive, which is expensive.
  • herbal medicine is acupuncture and aromatherapy, physiotherapy, drug therapy will be treated, these treatments also have a temporary symptomatic effect, it is not effective to cure rhinitis.
  • the present invention comprises a nasal wash composition
  • a nasal wash composition comprising the marine mineral water taken from the 1100m underground of the hot spring area of the coastal Dangu district 92-1, Geumjin 3-ri, Okgye-myeon, Gangneung-si, Gangwon-do, South Korea as an active ingredient to provide.
  • the mineral water is a mineral component, potassium 200 ⁇ 230mg / L, sodium 7000 ⁇ 9500mg / L, calcium 1400 ⁇ 1700mg / L, magnesium 900 ⁇ 1100mg / L, zinc 3 ⁇ 9mg / L , Strontium 25 ⁇ 35mg / L, Selenium 200 ⁇ 500ug / L, Vanadium 65 ⁇ 75ug / L, Germanium 0.5 ⁇ 1.5ug / L, Manganese 10 ⁇ 40ug / L, Cobalt 1-3ug / L, Titanium 600 ⁇ 950ug / L , Copper 3 ⁇ 9ug / L, lithium 0.02 ⁇ 0.09mg / L, chlorine ion 16000 ⁇ 19500mg / L, fluorine ion 1.5 ⁇ 3.0mg / L, bromine ion 40 ⁇ 56mg / L, sulfate ion 3000 ⁇ 4
  • the mineral water is a concentrate
  • the concentrate may be contained in 0.5 to 50% (v / v) based on the total weight of the composition.
  • the composition may be a liquid, paste, ointment, or spray formulation.
  • the present invention provides a composition for the prevention or treatment of rhinitis or sinusitis, including the marine mineral water taken from the 1100m underground of the hot spring area of the waterfront district 92-1 Geumjin 3-ri, Okgye-myeon, Gangneung-si, Gangwon-do, South Korea.
  • the mineral water is a mineral component, potassium 200 ⁇ 230mg / L, sodium 7000 ⁇ 9500mg / L, calcium 1400 ⁇ 1700mg / L, magnesium 900 ⁇ 1100mg / L, zinc 3 ⁇ 9mg / L , Strontium 25 ⁇ 35mg / L, Selenium 200 ⁇ 500ug / L, Vanadium 65 ⁇ 75ug / L, Germanium 0.5 ⁇ 1.5ug / L, Manganese 10 ⁇ 40ug / L, Cobalt 1-3ug / L, Titanium 600 ⁇ 950ug / L , Copper 3 ⁇ 9ug / L, lithium 0.02 ⁇ 0.09mg / L, chlorine ion 16000 ⁇ 19500mg / L, fluorine ion 1.5 ⁇ 3.0mg / L, bromine ion 40 ⁇ 56mg / L, sulfate ion 3000 ⁇ 4
  • the mineral water is the mineral water is a concentrate
  • the concentrate may contain 0.5 to 50% (v / v) based on the total weight of the composition.
  • the mineral water may be to reduce the swelling of the intranasal mucosa due to inflammation, and to reduce the expression of MUC5AC gene, a mucus hypersecretion-inducing factor.
  • composition for nasal washing and the composition for the prevention or treatment of rhinitis or sinusitis caused by inflammation, etc. containing marine mineral water taken from 1100m underground of the hot spring area of 92-1, Geumjin 3-ri, Okgye-myeon, Gangneung-si, Gangwon-do, South Korea according to the present invention It has the effect of reducing the swelling and thickness of the nasal mucosa, and also improves the degree of inflammation, and also has an excellent effect of reducing the expression of substances that induce mucus hypersecretion, thereby improving, preventing and improving nasal disease symptoms such as sinusitis and rhinitis. There is an effect that can be widely used in the manufacture of treatable nasal washes and therapeutic agents and functional health foods.
  • Figure 1 shows a microscopic view of the thickness of the nasal mucosa in rats induced by rhinosinusitis by LPS injection in the rat model, (a) is nothing treated, (b) saline solution Group treated with, (c) shows a group treated with LPS.
  • FIG. 2 shows a photograph of the same mouse group as shown in FIG. 1 when observed with a microscope, and the arrow indicates the site of the increased PAS.
  • Figure 3 shows the pictures observed by the Evans blue reagent staining effect on the vascular outflow due to inflammation in the same rat group as in Figure 1, the arrow shows the Evans blue staining with increased mucosal outflow.
  • Figure 4 shows a photograph observed by Evans blue reagent staining effect of inflammation due to mineral water treatment according to the present invention
  • A is a group not treated anything
  • B is a group treated only saline
  • C is LPS-treated group
  • D treated with LPS and saline
  • E treated with LPS and 25% mineral water
  • F treated with LPS and 50% (v / v) mineral water
  • One group, G represents the group treated with LPS and 100% (v / v) mineral water
  • Figure 6 shows the result of observing the nasal mucosa thickness of the microscope through hematoxylene-eosin staining after separating the nasal mucosa tissue from each rat group of FIG.
  • FIG. 7 shows the result of FIG. 6 as a bar graph.
  • FIG. 8 is a mineral water according to the present invention in order to determine whether there is an effect of inhibiting the expression of the mucus hypersecretion inducing factor MUC5AC gene, after taking nasal tissue from each rat group of Figure 4, which can amplify the MUC5AC gene RT-PCR using the primers are shown.
  • the present invention is characterized in that it provides a new nasal cleaning composition comprising mineral water excellent in nasal washing effect and particularly excellent in reducing nasal mucosal edema and mucus hypersecretion due to inflammation.
  • Mineral water contained as an active ingredient in the nasal cleaning composition according to the present invention is characterized in that it is marine mineral water taken from the 1100m underground of the hot spring area of 92-1, Geumjin 3-ri, Okgye-myeon, Gangneung-si, Gangwon-do, South Korea.
  • seawater In general, seawater is called deep seawater, which is distinguished from surface water, and deep sea water refers to seawater 200 meters or less from the surface of seawater. It contains many inorganic nutrients such as nitrogen, phosphorus, and silicic acid needed for plant growth because photosynthesis does not occur. It is known that it is not polluted by air or chemicals and contaminated with solar bacteria or general bacteria, and has a small number of benign bacteria, so that the physical cleanliness is excellent.
  • nasal diseases caused by colds, sinusitis and allergic rhinitis cause headaches, sleep deprivation, coughing, stress, etc. in modern times, which greatly reduces the quality of life of the individual. It causes a loss of social costs.
  • recent statistics show that about 15% of the total population has sinusitis and about 30% have allergies, costing about $ 2.4 billion and $ 3.4 billion in medical costs annually.
  • research on nasal lavage that can increase the therapeutic effect is increasing.
  • Nasal lavage is known to be a very effective way to improve mucus islet function, reduce swelling of the nasal mucosa, reduce the activity of inflammation-related factors and cleanse concentrated mucus (Tomooka LT et al., Clinical study and literature review of nasal irrigation. , Laryngoscope. 2000 Jul; 110 (7): 1189-93).
  • the present inventors are developing a wash water that can wash the nasal cavity using marine mineral water, and marine mineral water, which is a deep seawater that is eluted from a rock bed of 1100m underground in the hot spring area, 92-1, Geumjin 3-ri, Okgye-myeon, Gangneung-si, Gangwon-do, Korea It was confirmed that the symptoms of the disease, mucosal edema, inflammatory factor activity and concentrated mucus removal effect is excellent, and that the mineral water is very suitable for use as a nasal cleaning composition.
  • the vascular outflow due to the inflammatory flow path was stained with Evans blue dye, and as a result, nothing In comparison with the non-treated rats, LPS-induced rhinosinusitis significantly increased the outflow of Evans blue dye due to inflammation, and the outflow of Evans blue dye was reduced by the mineral water injection of the present invention.
  • the group treated with 50% (v / v) and 100% (v / v) of the mineral water of the present invention has a higher outflow of Evans blue dye compared to the physiological saline treatment group used for nasal washing. It was found to be reduced (see FIGS. 3 and 4).
  • the mineral water of the present invention has an effect of reducing nasal mucosa thickness, a symptom of nasal disease.
  • the nasal mucosa was significantly thicker than that of normal rats in which the rhinosinusitis was induced by LPS, whereas the mineral water of the present invention was increased due to LPS.
  • the nasal mucosa thickness was shown to be reduced and this decrease was proportional to the concentration of treated mineral water (see FIGS. 5 and 6).
  • the present inventors have found that the mineral water of the present invention can be used for nasal washing, which can prevent and improve nasal diseases caused by inflammation and allergy, and in particular, the mineral water of the present invention for nasal washing. It can be seen that when contained in more than 50% (v / v) based on the composition it can induce better efficacy.
  • the present inventors investigated whether the mineral water of the present invention can affect the causative factors of nasal diseases such as rhinitis and sinusitis.
  • MUC5AC is known to induce hypersecretion of mucus.
  • the expression level of the factor was analyzed in the mouse models tested above. That is, after separating the nasal mucosa tissue from the group treated with physiological saline to LPS-induced rhinosinusitis-induced rhinosinusitis-treated rats and the rhinosinus-induced rats treated with mineral water of the present invention by concentration, RNA was extracted and the expression level of MUC5AC gene in each tissue was analyzed by RT-PCR using primers specific for MUC5AC gene.
  • MUC5AC was used in the rat group that induced rhinosinusitis with LPS compared to the normal rat group that was not treated with anything. While the expression of the gene was increased by about three times or more, in the group treated with saline and mineral water of the present invention, the expression of the MUC5AC gene was found to be decreased compared to the rat group induced by rhinosinusitis with LPS, in particular physiological. Compared to the saline treatment group, the mineral water treatment group of the present invention was shown to more effectively reduce the expression of the MUC5AC gene. Was (see Fig. 6).
  • the mucosal ciliary system serves as the primary defense mechanism for transporting inhaled particles or infectious agents out of the airways.
  • the substances present in the airway sera are known to limit the toxicity of the particles and to inactivate infectious agents, and the physical mechanism of coughing is known to play a role in draining mucus from the airway passages.
  • the mucosal ciliary system consists of ciliary epithelial cells, epithelial goblet cells, and serous and mucous cells located in the submucosal gland, and the cilia are active transport of chloride and passive transport of water across the epithelium through the lumen of the airway passage. It is surrounded by an aqueous layer (peripheral fluid) secreted by it and comes into contact with the floating mucus on the aqueous layer and provides for the movement of the mucus by a constant propulsion action.
  • aqueous layer peripheral fluid
  • mucus generally promotes removal of inhaled particles or infectious agents, but hypersecretion of mucus causes various diseases such as chronic bronchitis, acute asthma, cystic fibrosis, rhinitis, sinusitis and bronchiectasis.
  • the mineral water of the present invention has an inhibitory effect on the expression of the MUC5AC gene that induces the production of mucus, thereby improving, preventing and treating the symptoms of nasal diseases such as rhinitis and sinusitis.
  • the present invention can provide a nasal wash composition comprising the marine mineral water taken from the 1100m underground of the hot spring area of 92-1, Geumjin 3-ri, Okgye-myeon, Gangneung-si, Gangneung-si, Gangwon-do, South Korea.
  • the mineral water contained in the composition of the present invention as an active ingredient is a mineral component, potassium 200 ⁇ 230mg / L, sodium 7000 ⁇ 9500mg / L, calcium 1400 ⁇ 1700mg / L, magnesium 900 ⁇ 1100mg / L, zinc 3 ⁇ 9mg / L, Strontium 25 ⁇ 35mg / L, Selenium 200 ⁇ 500ug / L, Vanadium 65 ⁇ 75ug / L, Germanium 0.5 ⁇ 1.5ug / L, Manganese 10-40ug / L, Cobalt 1-3ug / L, Titanium 600 ⁇ 950ug / L, copper 3 ⁇ 9ug / L, lithium 0.02 ⁇ 0.09mg / L, chlorine ion 16000 ⁇ 19500mg / L, fluorine ion 1.5 ⁇ 3.0mg / L, bromine ion 40 ⁇ 56mg / L, sulfate ion 3000
  • This component analysis is a result of the mineral component analysis of the mineral water according to the present invention commissioned by the Korea Institute of Science and Technology (KIST), the Korea Basic Science Institute (KBSI) and the Korea Institute of Geoscience and Mineral Resources (KIGAM). Mineral waters are new to date.
  • KIST Korea Institute of Science and Technology
  • KBSI Korea Basic Science Institute
  • KIGAM Korea Institute of Geoscience and Mineral Resources
  • the mineral water may use the marine mineral water itself taken from the 1100m underground of the hot spring area, 92-1, Geumjin 3-ri, Okgye-myeon, Gangneung-si, Gangneung-si, Gangwon-do, South Korea, the mineral water is the total weight of the composition It can be used in an amount of 50% (v / v) to 100% (v / v) as a standard, or can be prepared and used as a concentrate, and when used as a concentrate, 0.5 to 50% based on the total weight of the composition It can be contained and used in the quantity of (v / v).
  • the concentrate may be a solid obtained by evaporating, concentrating and drying the mineral water according to the present invention, or may be a concentrate obtained by evaporating the mineral water by natural drying or by artificially desalting and drying (or evaporating) the mineral water.
  • the concentrate of the mineral water according to the present invention may be prepared by the following method.
  • the filtration step may be subjected to a plurality of filtration steps, in the present invention was carried out a four-step filtration process. That is, the first stage filtration was removed by filtering the suspended matter more than 10um, and then removed by filtering the suspended matter more than 5um again as a second stage filtration, and then removed by filtering the suspended matter above 1um as a three-step filtration.
  • the suspended solids filtered by 0.2um or more by a four-step filtration process.
  • the desalination is not limited thereto, but may be used an electrodialysis machine.
  • desalination powder is prepared through a drying step using natural drying or an artificial dryer.
  • a vacuum freeze dryer was used for the drying.
  • the desalted powder can be ground and packed.
  • the preparation of the concentrate of the mineral water according to the present invention may be carried out first through the drying process after collecting the raw water, and then performing the filtration step.
  • the nasal washing composition according to the present invention may further include a conventional therapeutic anti-allergic agent or anti-inflammatory agent suitable for improving nasal disease symptoms such as rhinitis and sinusitis, and also for flavoring, coloring, It may further include additives such as fungicides, antioxidants, preservatives, humectants, thickeners, inorganic salts, emulsifiers, synthetic polymer materials.
  • the administration method of the nasal washing composition according to the present invention is not limited thereto, but a spray method, a squeeze method, or an administration method by an electric machine may be used, and may be used in any formulation form, but is convenient for washing. It is preferable to be a liquid so that it may be manufactured and used also in paste form, ointment, spray formulations, etc.
  • the present invention can provide a composition for the prevention or treatment of rhinitis or sinusitis, which contains marine mineral water taken at 1100m underground from the hot spring area of 92-1, Geumjin 3-ri, Okgye-myeon, Gangneung-si, Gangwon-do, Korea.
  • composition of the present invention can be used as a pharmaceutical composition for the prophylaxis or treatment of nasal diseases such as rhinitis or sinusitis, when the concentrated mineral water according to the present invention is used in a concentration of 0.5 to 50% by weight relative to the total weight of the composition can do.
  • composition for the prophylaxis or treatment of rhinitis or sinusitis comprises a pharmaceutically effective amount of mineral water itself or mineral water concentrate according to the present invention alone or at least one pharmaceutically acceptable carrier, excipient or diluent It may include.
  • the pharmaceutically effective amount herein refers to an amount sufficient to prevent, ameliorate or treat rhinitis or sinusitis.
  • the pharmaceutically effective amount of mineral water concentrate according to the invention is 0.5-100 mg / day / kg body weight, preferably 0.5-5 mg / day / kg body weight.
  • the pharmaceutically effective amount may be appropriately changed according to the degree of symptoms of the disease, the age, weight, health condition, sex, route of administration, and duration of treatment of the patient.
  • pharmaceutically acceptable refers to a composition that is physiologically acceptable and does not normally cause an allergic reaction, such as gastrointestinal disorders, dizziness, or the like when administered to a human.
  • carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Polyvinylpyrrolidone, water, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil.
  • fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers and preservatives may be further included.
  • compositions for the prophylaxis and treatment of rhinitis or sinusitis of the present invention may be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
  • the formulations may be in the form of powders, granules, tablets, emulsions, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, sterile powders.
  • composition according to the invention can be administered via several routes including oral, transdermal, subcutaneous, intravenous or intramuscular, the dosage of the active ingredient being determined by several factors such as the route of administration, the age, sex, weight and severity of the patient. It may be appropriately selected depending on.
  • composition of the present invention can be administered in parallel with known compounds having the effect of preventing, improving or treating rhinitis or sinusitis.
  • the present invention can provide a rhinitis or sinusitis medicament comprising a composition containing mineral water taken from 1100m underground in the hot spring area of Geumjin-ri Coastal Area.
  • composition according to the present invention not only provides the excellent rhinitis or sinusitis inhibitory effect, but also is safer than conventional chemical preparations based on natural deep sea water, and does not have any toxic and side effects on the drug even when taken for a long time. Can be used with confidence.
  • the composition of the present invention can be added to a food for the purpose of preventing or treating a disease caused by rhinitis or sinusitis, and thus can be used as a food composition for the prevention and improvement of disease symptoms caused by rhinitis or sinusitis. have.
  • the "food” means a natural product or processed product containing one or more nutrients, and preferably means a state in which it can be directly eaten through a certain processing step, and a general meaning As used herein, it refers to food, food additives, functional foods and beverages.
  • Foods to which the composition according to the present invention can be added include, for example, various foods, beverages, gums, teas, vitamin complexes, functional foods, and the like.
  • food includes special nutritional products (e.g., formulated milk, young, infant food, etc.), processed meat products, fish products, tofu, jelly, noodles (e.g. ramen, noodles, etc.), bread, health supplements, seasonings.
  • Foods e.g. soy sauce, miso, red pepper paste, mixed soy sauce
  • sauces confectionery (e.g. snacks), candy, chocolates, gums, ice creams, dairy products (e.g.
  • fermented milk, cheese, etc. other processed foods
  • kimchi, Pickled foods various kimchi, pickles, etc.
  • beverages e.g., fruit drinks, vegetable drinks, soy milk, fermented beverages, etc.
  • natural seasonings e.g. ramen soup, etc.
  • the food, beverage or food additives may be prepared by a conventional manufacturing method.
  • the term "functional food” refers to the control of biological defense rhythms and disease prevention of food groups or food compositions that have added value to the food by using physical, biochemical, or biotechnological techniques to act and express the function of the food for a specific purpose. It means a food that is designed and processed to fully express the body's regulatory function regarding recovery and the like, and specifically, it may be a health functional food.
  • the functional food may include food acceptable food additives, and may further include appropriate carriers, excipients and diluents commonly used in the manufacture of functional foods.
  • the "beverage” refers to a generic term for drinking to quench thirst or to enjoy a taste and includes a functional drink.
  • the beverage contains, as the essential ingredient, the composition for treating and preventing rhinitis or sinusitis according to the present invention as an essential ingredient, and there are no special limitations, and various flavors or natural carbohydrates are added as in the general beverage. It may contain as a component.
  • foods containing the composition of the present invention include various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavoring agents, colorants and fillers (such as cheese and chocolate), and pectic acid. And salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like, which components may be independently or in combination Can be used.
  • the amount of the composition according to the present invention may comprise from 0.001% to 90% by weight of the total food weight, preferably from 0.1% to 40% by weight.
  • the amount of the composition according to the present invention may comprise from 0.001% to 90% by weight of the total food weight, preferably from 0.1% to 40% by weight.
  • it may be included in a ratio of 0.001g to 2g, preferably 0.01g to 0.1g based on 100ml, in the case of long-term intake for health and hygiene purposes or health control purposes It may be less than the range, the active ingredient is not limited to the above range because it may be used in an amount above the range because there is no problem in terms of safety.
  • the present invention can provide a health functional food for the prevention or improvement of rhinitis or sinusitis containing mineral water or mineral water concentrate according to the present invention as an active ingredient
  • the form of the food is not limited thereto, powder, It may be in the form of granules, tablets, capsules or beverages.
  • the present inventors collected the hot spring water taken from the 110m underground bedrock in the Geumjin-ri beach coastal area of Okgye-myeon, Gangneung-si, Gangneung-si, Gangwon-do, to collect mineral water that can be effectively used for nasal washing, and filtered by using a 0.25 micrometer line filter. After removing the contaminants, it was desalted using an electrodialysis machine (voltage: 5.5-7.5 V, electrode solution: 3% Na 2 SO 4, CJTTS-2-10 ED, Creative Techno). After the desalination process was filtered and dried using a vacuum freeze dryer (temperature: -40 ⁇ 30 °C, vacuum degree: 5mTorr), the mineral water concentrate of the present invention prepared by this process in the following experiment Used.
  • Example 1 In order to determine whether the mineral water of the present invention according to Example 1 is suitable for use for nasal washing, and furthermore, it is possible to treat rhinitis diseases such as rhinosinusitis, a rat model in which rhinosinusitis is induced was produced. That is, 250 mg of healthy, respiratory disease-free Sprague Dawley rats, LPS, a factor inducing rhinosinusitis, was extracted from Pseudomonas aeruginosa (L-4524, Sigma, St. Louis, Mo, USA). / ml) and injected into the nose of the mouse in an amount of 0.1ml to produce a rat model in which rhinosinusitis was induced.
  • rhinitis diseases such as rhinosinusitis
  • mice were raised in an environment free of pathogens, and were allowed to freely ingest sterile standard rat food (Ralston Purina, St. Louis, MO) and water. Animal experiments were conducted with the approval of the clergy University Institutional Animal Care and Use Committee. At this time, the control was used to inject Saline (physiological saline) solution in the rat nose instead of LPS.
  • Saline physiological saline
  • the experimental rat group was divided as follows, and the following experiment was performed.
  • the 25%, 50% and 100% mineral water means that the mineral water prepared in Example 1 diluted with physiological saline such that 25% (v / v), 50% (v / v), 100% refers to 100% mineral water concentrate, wherein LPS was prepared as described in Example 2, and the treatment group of A ⁇ G used the dose of 0.1ml in the amount of the nose of the rat. Injected into.
  • the degree of plasma outflow was investigated in the rat group treated with each solution by using Evans blue reagent, which is measured by measuring the degree of staining because the plasma outflow increases when inflammation of the nasal cavity increases. It is used to analyze the degree of inflammation in the nasal cavity.
  • the analysis of the degree of Evans blue effusion was first performed by injecting 1 ml of Evans blue solution (Sigma, 40 mg / ml in Salinee) into the external jugular vein of the mice, one minute after the injection, and a nasal tissue sample from each rat The samples were then immersed in 60 to 1 ml of formamide (Sigma, USA) for 24 hours.
  • the sample was centrifuged for 30 seconds at 9,000 rpm and 20 ° C., and then the absorbance of the supernatant obtained by centrifugation using a microplate reader (model 680, Biorad, USA) was measured at 630 nm.
  • Nasal mucosa was collected from each rat in each rat group (A-G) tested in Example 3, and the thickness of the mucosa was analyzed by hematoxylin-eosin staining.
  • mucosal thickness was significantly increased compared to the rat group in which no rhinosinus was induced, and treated with LPS and saline.
  • the thickness of the mucosa was found to be reduced compared to the group treated with LPS alone, and the decrease in the thickness of the mucosa was similar to the group treated with 50% of the mineral water of the present invention, and the mineral water of the present invention was 100%.
  • the treated group was found to have a lower mucosal thickness than the normal saline treated group.
  • the present inventors separated the nasal tissue from each rat group used in Example 3, extracted RNA from the tissue, and then extracted MUC5AC.
  • the expression level of the MUC5AC gene was analyzed by performing RT-PCR using a primer capable of amplifying the gene.
  • RNA was extracted using the extraction kit ((iNtRON Biotechnology, Inc., Gyeonggi-do, Korea) according to the user's proposed method, PCR reaction for MUC5AC was reacted for 15 minutes at 95 °C, 1 at 94 °C The reaction was repeated 32 times for 1 minute at 55 ° C. and 1 minute at 72 ° C.
  • PCR reaction of glyceraldehyde 3-phosphate dehydrogenase was performed at 94 ° C. for 4 minutes, at 94 ° C. for 1 minute, and at 60 ° C. The reaction was repeated 35 times for 1 minute at 72 ° C.
  • the primers used were designed by Gene Runner software (Hastings Software Inc., Las Vegas, Nev, USA) and purchased from GenBenk. The sequence of each primer is as follows.
  • GAPDH forward primer 5'-GCTGGTGCTGAGTATGTCGT-3 '
  • GAPDH reverse primer 3'-GAATGGGAGTTGCTGTTGAA-5 '
  • the expression of the MUC5AC gene which functions as a mucus hypersecretion, is significantly more than three times higher in the LPS-induced rhinosinusitis than in the non-treated group and the PBS-only group.
  • the expression of MUC5AC gene was decreased compared to the group treated with LPS alone, and the mineral water treated group of the present invention. was shown to decrease the expression of MUC5AC gene in proportion to mineral water concentration.
  • the present inventors have an effect of reducing the swelling and thickness of the nasal mucosa caused by inflammation, etc., in the case of mineral water according to the present invention, and also improves the degree of inflammation, MUC5AC inducing mucus hypersecretion It is also excellent in reducing the expression of the gene, it can be seen that it can be used as a nasal disease treatment and nasal wash water, such as sinusitis and rhinitis.
  • the inventors of the present invention to determine whether the mineral water according to the present invention can actually improve the symptoms of rhinitis and sinusitis patients, screening five patients for each experimental group three times a day determined by rhinitis and sinusitis at Catholic University St. Mary's Hospital (In morning weather, 2 pm, before bedtime) 10ml syringe was used to bow the head and the mineral water of the present invention was injected into the nasal cavity and waited for about 1 minute to let flow. This procedure was repeated for 10 days and the improved condition was evaluated on a 5 point scale on Day 5 and Day 10.
  • the mineral water used was a solution containing 50% (v / v) of mineral water concentrate in water. The results are shown in Table 3 below. At this time, only the saline was used as a control group and saline used for nasal washing for improving the symptoms of conventional rhinitis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition destinée au nettoyage de la cavité nasale contenant de l'eau minérale comme principe actif. Plus particulièrement, la présente invention concerne une composition destinée au nettoyage de la cavité nasale et une composition de prévention ou de traitement d'une rhinite ou d'une infection des sinus, comprenant, comme composant minéral, 200 à 230 mg/l de potassium, 7000 à 9500 mg/l de sodium, 1400 à 1700 mg/l de calcium, 900 à 1100 mg/l de magnésium, 3 à 9 mg/l de zinc, 25 à 35 mg/l de strontium, 200 à 500 µg/l de sélénium, 65 à 75 µg/l de vanadium, 0,5 à 1,5 µg/l de germanium, 10 à 40 µg/l de manganèse, 1 à 3 µg/l de cobalt, 600 à 950 µg/l de titane, 3 à 9 µg/l de cuivre, 0,02 à 0,09 mg/l de lithium, 16000 à 19500 mg/l d'ion chlorure, 1,5 à 3,0 mg/l d'ion fluorure, 40 à 56 mg/l d'ion bromure, 3000 à 4500 mg/l d'ion sulfate, 0,8 à 1,2 mg/l de bore et 0,5 à 15 mg/l de dioxyde de silicium.
PCT/KR2012/010154 2011-11-28 2012-11-28 Composition destinée au nettoyage de la cavité nasale contenant de l'eau minérale WO2013081366A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0125138 2011-11-28
KR1020110125138A KR101326472B1 (ko) 2011-11-28 2011-11-28 광천수를 함유한 비강 세척용 조성물

Publications (1)

Publication Number Publication Date
WO2013081366A1 true WO2013081366A1 (fr) 2013-06-06

Family

ID=48535756

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/010154 WO2013081366A1 (fr) 2011-11-28 2012-11-28 Composition destinée au nettoyage de la cavité nasale contenant de l'eau minérale

Country Status (2)

Country Link
KR (1) KR101326472B1 (fr)
WO (1) WO2013081366A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016028504A1 (fr) * 2014-08-16 2016-02-25 SOFIBEL S.A.S. - a company ultimately owned by CHURCH & DWIGHT CO. INC. Composition nasale ayant des propriétés anti-virales
WO2022254042A1 (fr) * 2021-06-04 2022-12-08 Olys Pharma Srl Complexe pluri-ionique pour la prévention ou le traitement d'une inflammation neurogène
WO2023232997A1 (fr) * 2022-06-03 2023-12-07 Ynios Pharma Complexe multi-ionique pour la prévention ou le traitement de l'inflammation

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2637438C1 (ru) * 2016-12-28 2017-12-04 Ирина Евгеньевна Куранчева Средство для промывания носовой полости, носоглотки и полости рта
KR102227420B1 (ko) 2017-06-30 2021-03-15 대봉엘에스 주식회사 비강 세정용 조성물
RU2665959C1 (ru) * 2017-11-21 2018-09-05 Андрей Никифорович Васильев Спрей для экстренной профилактики острых респираторных вирусных инфекций

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247446A (ja) * 2000-03-06 2001-09-11 Toa Yakuhin Kk 深層水配合洗浄薬
JP2002212081A (ja) * 2001-01-23 2002-07-31 Goshu Yakuhin Kk 海洋深層水配合鼻洗浄剤
KR20040031799A (ko) * 2002-10-01 2004-04-14 임 그리워 반도심층수 농축물을 함유한 항알러지 활성을 갖는약학조성물
KR20050021201A (ko) * 2003-08-26 2005-03-07 진해개발주식회사 해양 암반 심층수 농축물을 유효성분으로 함유한 항알러지조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101171068B1 (ko) * 2010-04-01 2012-08-03 주식회사 동양생명과학 미네랄 조성물을 유효 성분으로 함유하는 당뇨 개선 및 예방용 약학적 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247446A (ja) * 2000-03-06 2001-09-11 Toa Yakuhin Kk 深層水配合洗浄薬
JP2002212081A (ja) * 2001-01-23 2002-07-31 Goshu Yakuhin Kk 海洋深層水配合鼻洗浄剤
KR20040031799A (ko) * 2002-10-01 2004-04-14 임 그리워 반도심층수 농축물을 함유한 항알러지 활성을 갖는약학조성물
KR20050021201A (ko) * 2003-08-26 2005-03-07 진해개발주식회사 해양 암반 심층수 농축물을 유효성분으로 함유한 항알러지조성물

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016028504A1 (fr) * 2014-08-16 2016-02-25 SOFIBEL S.A.S. - a company ultimately owned by CHURCH & DWIGHT CO. INC. Composition nasale ayant des propriétés anti-virales
WO2022254042A1 (fr) * 2021-06-04 2022-12-08 Olys Pharma Srl Complexe pluri-ionique pour la prévention ou le traitement d'une inflammation neurogène
BE1029458B1 (fr) * 2021-06-04 2023-01-09 Olys Pharma Complexe pluri-ionique pour la prévention ou le traitement de l'inflammation neurogène
WO2023232997A1 (fr) * 2022-06-03 2023-12-07 Ynios Pharma Complexe multi-ionique pour la prévention ou le traitement de l'inflammation
BE1030588B1 (fr) * 2022-06-03 2024-01-08 Ynios Pharma Complexe pluri-ionique pour la prévention ou le traitement de l'inflammation

Also Published As

Publication number Publication date
KR101326472B1 (ko) 2013-11-08
KR20130059048A (ko) 2013-06-05

Similar Documents

Publication Publication Date Title
WO2013081366A1 (fr) Composition destinée au nettoyage de la cavité nasale contenant de l'eau minérale
CN103735581B (zh) 一种鼻腔清洁护理溶液及其制配方法
WO2012068730A1 (fr) Composition de dentifrice pour l'hygiène dentaire
CN103768405A (zh) 一种中药消毒液及制备方法
CN103301254B (zh) 一种鼻咽腔道用抗菌液及其制备方法
CN102940595A (zh) 一种具有抗菌消炎脱臭的漱口液及其制备方法和用途
CN113332244B (zh) 一种抗病毒口腔喷剂及制备方法
CN101632754B (zh) 一种治疗咽炎的中药组合物及其制备方法
US20160303179A1 (en) Plant-based composition for use in the treatment of cough
KR20220010980A (ko) 대마 추출물을 유효성분으로 포함하는 항균 및 항바이러스 조성물
CN108066224B (zh) 一种安胃疡牙膏及其制备方法
CN107913234B (zh) 一种鹿茸草牙膏及其制备方法
CN105031477A (zh) 泳后口腔食道杀菌药剂
CN113413444A (zh) 一种鼻腔冲洗液及其制备方法
CN102670855B (zh) 一种治疗鼻后滴流综合征的中药组合物及其制备方法
CN116251160B (zh) 一种具有抑菌作用的药物组合物及其制备方法和用途
TWI843562B (zh) 朝鮮薊萃取物用以製備治療阿茲海默症的藥物的用途
CN104906379A (zh) 一种治疗大疱性脓包疮的中药软膏及其制备方法
Ashour et al. Anthelmintic potential of sulphonamides and Cucurbita pepo seeds extract on Heterophyes heterophyes experimentally infected mice
CN117797217A (zh) 一种速愈治疗皮肤病的中药外用喷剂
CN104958400A (zh) 一种治疗急性结膜炎的眼膏及其制备方法
RU2191025C2 (ru) Лекарственное растительное средство для лечения аллергических болезней
WO2023003121A1 (fr) Composition pour inhiber la prolifération de coronavirus
CN117100832A (zh) 一种中药抑菌喷雾剂组合物及其制备方法
CN111632109A (zh) 机体免疫保护与病毒防治剂及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12852642

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12852642

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载